CClinicalTrials.gg
CompletedNCT02379702Updated Mar 5, 2015

Metabolic Syndrome Prevalence Study

An observational study in Metabolic Syndrome, sponsored by Abdi Ibrahim Ilac San. ve Tic A.S.. Completed at 6 sites in Turkey. Per ClinicalTrials.gov, last updated 2015-03-05.

Sponsored by Abdi Ibrahim Ilac San. ve Tic A.S. · Observational

Study type
Observational
Time perspective
Prospective
Enrollment
1,659
Sex
All
01

Study summary

Following the first study conducted to investigate the prevalence of metabolic syndrome and its components in Turkey, it was aimed to demonstrate the change in general health condition of available patients after the period of time lapsed. This study will provide important information on the social and economic dimensions of metabolic syndrome and will contribute to development of preventive programs.

Read the detailed description

In the first METSAR-I study conducted in 2003, metabolic syndrome screening was made by two different team. Participants were visited at their addresses and informed about the research study and gave written consent. They were invited on an empty stomach for hospital visit on the day after. Pre-trained nurses completed the forms of patients during that second visit. After 11 years, a questionnaire by telephone survey will be applied to patients who participated in the METSAR-II study. The main goal is to determine the changes of metabolic syndrome population during that period.

02

Conditions studied

  • Metabolic Syndrome
03

In context

Metabolic Syndrome

1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.

This study's enrollment of 1,659 is above the median of 200 across 458 observational studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

Abdi Ibrahim Ilac San. ve Tic A.S. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The previous study included 4.264 patients from 47 cities and we are going to try to get in contact all those patients. Data obtained from available patients will be analysed and the change trend will be evaluated

Inclusion criteria

  • Volunteers who participated in the METSAR-I study in 2003
  • Patients who accepted to participate will be included the second follow up phase.

Exclusion criteria

Exclusion Criteria:

None

05

Study design

Time perspective
Prospective
Enrollment
1,659 participants (actual)
Target follow-up
10 Years
Patient registry
Yes

Interventions

  • OtherMetabolic Syndrome

    This study will provide important information on the social and economic dimensions of metabolic syndrome

06

What researchers measure

Primary outcomes

  1. comorbidities and changes in general health

    Time frame: 10 year

07

Study locations

6 sites
  • Ankara University
    Ankara, Turkey
  • Gazi University
    Ankara, Turkey
  • Yuksek Ihtisas Hospital
    Ankara, Turkey
  • Istanbul Cerrahpasa University
    Istanbul, Turkey
  • Istanbul Medeniyet University
    Istanbul, Turkey
  • Prof. Dr. Omer Kozan
    İzmir, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02379702
Lead sponsor
Abdi Ibrahim Ilac San. ve Tic A.S.
Responsible party
Sponsor
First posted
Mar 5, 2015
Start date
Jun 2014
Primary completion
Nov 2014
Completion
Nov 2014
Last update
Mar 5, 2015

Study contacts

Omer Kozan
study director · Dokuz Eylul University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion